Rare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.
Company Details
- Founded
- -
- Address
- Teatergatan 3, Stockholm,stockholm County 111 48,sweden
- In****@****oid.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- rarethyroid.com
- Keywords
- orphan drugs, Clinical trials, Endocrinology, Neurology, Pediatric, Pharmaceutical development, MCT8 deficiency, Thyroid hormone signalling, AHDS.
- HQ
- Stockholm, Stockholm County
Rare Thyroid Therapeutics Questions
Rare Thyroid Therapeutics's website is rarethyroid.com
Rare Thyroid Therapeutics's LinkedIn profile is https://se.linkedin.com/company/rarethyroid
Rare Thyroid Therapeutics's industry is
Pharmaceutical Manufacturing
Rare Thyroid Therapeutics's top competitors are
Utisolve Research Group,
Atb Sverige,
Eribis Pharmaceuticals,
Biotech-Igg,
Immedica Pharma Ab,
Innate Pharmaceuticals Ab,
Junvik Consulting,
Lithea Ab (Former Moroxite T Ab),
Morenco Pharma Ab,
Egetis Therapeutics Ab.
Rare Thyroid Therapeutics's support email address is Info@rarethyroid.com
Rare Thyroid Therapeutics's categories are Pharmaceutical Manufacturing
Rare Thyroid Therapeutics's founding year is 2017
